Skip to main content

Table 2 Randomized phase II clinical trials in oestrogen receptor-positive metastatic breast cancer

From: New targets for therapy in breast cancer: Farnesyltransferase inhibitors

Combination Clinical setting Number of patients Primary end-point Trial group
Letrozole ± tipifarnib 2nd line 108 ORR J&J-INT-22
Letrozole ± tipifarnib 1st/2nd line 100+ ORR CALGB
Anastrazole ± lonarfarnib 1st line 110 ORR Schering
  1. ORR, objective response rate.